Spots Global Cancer Trial Database for Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults

Official Title: Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults

Study ID: NCT02496520

Conditions

Sarcoma

Central Nervous System Tumor

Interventions

dendritic cells

Surgery as needed by the patient´s tumor and stage

Chemotherapy as needed by the patient´s tumor and stage

Radiation therapy as needed by the patient´s tumor and stage

Study Description

Brief Summary: Phase I/II, open, prospective clinical trial, historically controlled. The objective is to evaluate the safety and, as a secondary measure, the efficacy of an experimental treatment based on a cellular therapy (vaccination with autologous dendritic cells pulsed with tumor lysate) in patients affected of metastatic or relapsed sarcomas or (Central Nervous System) CNS tumors.

Detailed Description: Phase I/II, open, prospective clinical trial, historically controlled. Patients affected of metastatic or relapsed sarcomas or (Central Nervous System) CNS tumors will be included. The patients will receive standard treatment and experimental treatment based on a cellular therapy with vaccination with autologous dendritic cells pulsed with tumor lysate. The immunization schedule includes 4 monthly vaccines, 4 bimonthly and quarterly remaining vaccines. The vaccines will be administered intradermally in combination with standard treatment for each type of tumor.